You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Antidiabetic agents

Showing 1 - 25 of 5,670
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diabetes, Type 2 Trial (Empagliflozin 25 MG, INS)

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Empagliflozin 25 MG
  • INS
  • (no location specified)
Jul 19, 2022

Glucose Metabolism Disorders, Diabetes, Type 2, Hypoglycemic Agents Trial in Karachi (Empagliflozin 10 MG,

Recruiting
  • Glucose Metabolism Disorders
  • +3 more
  • Empagliflozin 10 MG
  • Insulin+Metformin+DPP4 inhibitor (DPP4I)
  • Karachi, Pakistan
    SINA Shireen Jinnah colony
Nov 28, 2023

Stroke, Ischemic, Mild Cognitive Impairment, Dementia, Vascular Trial in León (Dapagliflozin 10mg Tab, Statins (Cardiovascular

Recruiting
  • Stroke, Ischemic
  • +3 more
  • Dapagliflozin 10mg Tab
  • +3 more
  • León, Guanajuato, Mexico
    Hospital General de Zona IMSS 21
Oct 3, 2022

Diabetes, Type 2 Trial (Prednisone)

Not yet recruiting
  • Diabetes Mellitus, Type 2
  • (no location specified)
Apr 22, 2020

Type 2 Diabetes Trial in United States (Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy)

Terminated
Has Results
  • Type 2 Diabetes Mellitus
  • Insulin glargine/Lixisenatide
  • +2 more
  • Montgomery, Alabama
  • +84 more
Mar 21, 2022

Type 2 Diabetes Trial in Worldwide (Placebo, Exenatide)

Completed
Has Results
  • Type 2 Diabetes
  • Birmingham, Alabama
  • +52 more
Nov 6, 2020

Impaired Glucose Tolerance, Insulin Sensitivity, Glucose Metabolism Disorders Trial in Oslo (Metformin capsule 500 mg,

Recruiting
  • Impaired Glucose Tolerance
  • +2 more
  • Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg
  • Oslo, Norway
    Oslo University Hospital, Aker Hospital
Apr 5, 2021

Semaglutide in Type 2 Diabetes - A Cohort Study Based on Nordic

Enrolling by invitation
  • Diabetes Mellitus, Type 2
  • Odense, Denmark
    Novo Nordisk Investigational Site
Nov 30, 2022

Novel Antidiabetic Medications and Their Effect on Liver

Completed
  • Non-Alcoholic Fatty Liver Disease
  • Liver Steatosis
  • Athens, Attiki, Greece
    "Hippocration" General Hospital of Athens
Jul 13, 2023

SGLT2 Inhibitors on Cognitive Functions and BDNF Levels in Type

Terminated
  • Type2 Diabetes
  • Cognitive Impairment
  • MOCA cognitive evaluation test
  • +3 more
  • Istanbul, Turkey
    Istanbul Medeniyet University Goztepe Research and Training Hosp
Apr 16, 2022

Diabetic Retinopathy Trial in Cairo (Dapagliflozin 10mg Tab plus another oral hypoglycemic agent, Two oral hypoglycemic agents

Recruiting
  • Diabetic Retinopathy
  • Dapagliflozin 10mg Tab plus another oral hypoglycemic agent
  • Two oral hypoglycemic agents other than dapagliflozin
  • Cairo, Egypt
    Internal medicine and endocrinology department, Ain-shams univer
Jun 9, 2022

Type2diabetes, Insulin Resistance Trial (Metformin, Dapagliflozin, Fixed-dose combination of metformin and pioglitazone (500mg

Not yet recruiting
  • Type2diabetes
  • Insulin Resistance
  • (no location specified)
Oct 20, 2022

Type 1 Diabetic Nephropathy Trial in Cairo (oral sitagliptin supplementation)

Completed
  • Type 1 Diabetic Nephropathy
  • oral sitagliptin supplementation
  • Cairo, Egypt
    Nancy Elbarbary
Nov 2, 2023

Type 2 Diabetes Trial in Worldwide (Sotagliflozin, Insulin glargine (HOE901), Placebo)

Completed
Has Results
  • Type 2 Diabetes Mellitus
  • Mesa, Arizona
  • +105 more
Apr 16, 2021

STEMI Trial in Cairo (Dapagliflozin)

Recruiting
  • STEMI
  • Cairo, Egypt
    Helwan University
Jul 16, 2023

SGLT2 Inhibitors on Heart Rate Variability and BDNF Levels in

Recruiting
  • Type 2 Diabetes
  • Heart Rate Variability
  • 24-hour rhythm Holter
  • 36 item Short Form Survey (SF-36)
  • Istanbul, Turkey
    Istanbul Medeniyet University Goztepe Research and Training Hosp
Dec 7, 2021

Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics Trial (Empagliflozin,

Not yet recruiting
  • Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics
  • (no location specified)
Jan 22, 2023

End Stage Kidney Disease Trial in Atlanta, Decatur (Continuous glucose monitoring (CGM))

Recruiting
  • End Stage Kidney Disease
  • Continuous glucose monitoring (CGM)
  • Atlanta, Georgia
  • +3 more
Feb 14, 2023

Ejection Fraction Trial in Seongnam (Gemigliptin, Glimepiride)

Recruiting
  • Ejection Fraction
  • Seongnam, Gyeonggi, Korea, Republic of
    Seoul National University Bundang Hospital
Dec 22, 2022

Type 2 Diabetes Trial in Marseille, Paris (1: incretin-based therapy, 2: other antidiabetic)

Recruiting
  • Type 2 Diabetes
  • 1: incretin-based therapy
  • 2: other antidiabetic
  • Marseille, France
  • +1 more
Jul 5, 2021

Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and

Completed
  • Leukemia
  • No Intervention
  • Cambridge, Massachusetts
    Takeda
Feb 28, 2023

Parkinson Disease Trial in Los Angeles (Liraglutide, Placebo)

Completed
  • Parkinson Disease
  • Los Angeles, California
    Cedars Sinai Medical Center
Oct 27, 2022

Type 2 Diabetes Trial in Chongqing (Liraglutide, Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation),

Completed
  • Type 2 Diabetes Mellitus
  • Liraglutide
  • Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Glinides
  • Chongqing, Chongqing, China
    The third hospital affiliated to the Third Military Medical Univ
Apr 30, 2022

Melanoma, NSCLC, Hepatocellular Carcinoma Trial in Pittsburgh (Nivolumab or Pembrolizumab (dependent upon approved indication),

Recruiting
  • Melanoma
  • +7 more
  • Nivolumab or Pembrolizumab (dependent upon approved indication)
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Feb 10, 2022

PreDiabetes Trial in Leon (Black bean protein hydrolysates (BPH), Commercial non-caloric beverage)

Completed
  • PreDiabetes
  • Black bean protein hydrolysates (BPH)
  • Commercial non-caloric beverage
  • Leon, Guanajuato, Mexico
    Universidad de Guanajuato
May 19, 2023